Sabatolimab - Novartis Oncology
Alternative Names: AntiTIM-3 monoclonal antibody Novartis; MBG-453; NVP-MBG453Latest Information Update: 18 Jun 2024
At a glance
- Originator Novartis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic myelomonocytic leukaemia
- Phase I/II Myelofibrosis; Solid tumours
- Phase I Myelodysplastic syndromes
- No development reported Glioblastoma
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 11 Jun 2024 Novartis Pharmaceuticals terminates the phase II STIMULUS-MDS3 trial in Myelodysplastic syndromes (Combination therapy) in Belgium, France, Germany, Greece, Hungary, Italy and Spain (IV), due to the strategic decision from the sponsor (EudraCT2020-003669-21) (NCT04812548)
- 17 May 2024 Novartis terminates a phase-I trial in Myelodysplastic syndromes (Monotherapy, Combination therapy, Second-line therapy or greater) in Spain, South Korea, Italy, Israel, Australia, USA (SC) due to business reasons (NCT04810611)
- 31 Dec 2023 Discontinued - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV)